Log in
Enquire now
‌

US Patent 10307370 Rapamycin for the treatment of lymphangioleiomyomatosis

Patent 10307370 was granted and assigned to AI Therapeutics on June, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
OrphAI Therapeutics
OrphAI Therapeutics
Current Assignee
OrphAI Therapeutics
OrphAI Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10307370
Date of Patent
June 4, 2019
Patent Application Number
15028365
Date Filed
October 7, 2014
Patent Citations Received
‌
US Patent 11744797 Rapamycin for the treatment of lymphangioleiomyomatosis
‌
US Patent 11648199 Inhalable rapamycin formulation for treating age-related conditions
0
‌
US Patent 11491143 Inhalable rapamycin formulation for the treatment of pulmonary hypertension
Patent Primary Examiner
‌
Robert A Wax
Patent abstract

The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10307370 Rapamycin for the treatment of lymphangioleiomyomatosis

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.